Ubs Group Ag Ice Cure Medical Ltd. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Ice Cure Medical Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 21,642 shares of ICCM stock, worth $15,365. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,642

Previous 14,876 45.48%

Holding current value

$15,365

Previous $14,000 50.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$0.79 - $1.19 $5,345 - $8,051	6,766 Added 45.48%	21,642 $21,000
Q2 2025 Aug 14, 2025	BUY	$0.92 - $1.26 $11,696 - $16,019	12,714 Added 588.07%	14,876 $14,000
Q1 2025 May 13, 2025	BUY	$1.08 - $1.55 $2,334 - $3,351	2,162 New	2,162 $2,000
Q3 2024 Nov 14, 2024	BUY	$0.58 - $0.83 $34,738 - $49,712	59,894 New	59,894 $36,000
Q4 2023 Feb 09, 2024	BUY	$0.72 - $1.36 $4,352 - $8,221	6,045 Added 40.87%	20,834 $22,000

Q3 2023 Nov 09, 2023	BUY	$0.54 - $1.33 $7,986 - $19,669	14,789 New	14,789 $7,000
Q1 2023 May 12, 2023	SELL	$1.05 - $1.49 $28,620 - $40,614	-27,258 Reduced 94.04%	1,728 $1,000
Q4 2022 Feb 08, 2023	BUY	$0.94 - $2.6 $25,303 - $69,989	26,919 Added 1302.32%	28,986 $44,000
Q3 2022 Nov 10, 2022	SELL	$1.12 - $2.03 $1,967 - $3,566	-1,757 Reduced 45.95%	2,067 $3,000
Q2 2022 Aug 10, 2022	SELL	$1.71 - $2.47 $418 - $605	-245 Reduced 6.02%	3,824 $7,000
Q1 2022 May 16, 2022	BUY	$2.01 - $3.31 $2,287 - $3,766	1,138 Added 38.83%	4,069 $10,000
Q4 2021 Feb 14, 2022	BUY	$2.73 - $8.7 $584 - $1,861	214 Added 7.88%	2,931 $9,000
Q3 2021 Nov 15, 2021	BUY	$8.61 - $11.33 $23,393 - $30,783	2,717 New	2,717 $24,000

Others Institutions Holding ICCM

# of Institutions

Shares Held

294K

Call Options Held

Put Options Held

View Full List

About IceCure Medical Ltd.

Ticker ICCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 36,835,600
Market Cap $26.2M
Description
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

More about ICCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account